Bank of New York Mellon
LPCN icon

Bank of New York Mellon’s Lipocine LPCN Stock Holding History

Bank of New York Mellon’s Portfolio LPCN Stock Details LPCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-3,115
Closed -$16.8K – 4435
2023
Q1 		$16.8K Hold
3,115
– – ﹤0.01% 4326
2022
Q4 		$21.1K Hold
3,115
– – ﹤0.01% 4349
2022
Q3 		$24K Hold
3,115
– – ﹤0.01% 4429
2022
Q2 		$42K Sell
3,115
-132
-4% -$2.06K ﹤0.01% 4381
2022
Q1 		$76K Hold
3,247
– – ﹤0.01% 4456
2021
Q4 		$55K Hold
3,247
– – ﹤0.01% 4485
2021
Q3 		$60K Sell
3,247
-3,236
-50% -$71.4K ﹤0.01% 4405
2021
Q2 		$154K Buy
6,483
+3,236
+100% +$76.1K ﹤0.01% 4145
2021
Q1 		$83K Sell
3,247
-335
-9% -$9.67K ﹤0.01% 4186
2020
Q4 		$83K Buy
+3,582
New +$86.2K ﹤0.01% 4100
2020
Q1 		– Sell
-815
Closed -$5K – 4154
2019
Q4 		$5K Hold
815
– – ﹤0.01% 4173
2019
Q3 		$39K Hold
815
– – ﹤0.01% 4142
2019
Q2 		$27K Sell
815
-16
-2% -$494 ﹤0.01% 4173
2019
Q1 		$33K Sell
831
-8
-1% -$245 ﹤0.01% 4126
2018
Q4 		$19K Hold
839
– – ﹤0.01% 4162
2018
Q3 		$20K Hold
839
– – ﹤0.01% 4209
2018
Q2 		$19K Sell
839
-1,576
-65% -$37.6K ﹤0.01% 4174
2018
Q1 		$62K Sell
2,415
-422
-15% -$11.7K ﹤0.01% 4138
2017
Q4 		$166K Sell
2,837
-34
-1% -$2.11K ﹤0.01% 3986
2017
Q3 		$193K Hold
2,871
– – ﹤0.01% 3886
2017
Q2 		$196K Sell
2,871
-2,598
-48% -$169K ﹤0.01% 3909
2017
Q1 		$362K Buy
5,469
+364
+7% +$23.6K ﹤0.01% 3689
2016
Q4 		$319K Buy
5,105
+1,962
+62% +$124K ﹤0.01% 3765
2016
Q3 		$239K Sell
3,143
-440
-12% -$27.3K ﹤0.01% 3844
2016
Q2 		$185K Sell
3,583
-1,115
-24% -$173K ﹤0.01% 3919
2016
Q1 		$811K Buy
4,698
+372
+9% +$63.5K ﹤0.01% 3188
2015
Q4 		$951K Sell
4,326
-142
-3% -$29.8K ﹤0.01% 3201
2015
Q3 		$898K Buy
+4,468
New +$1.03M ﹤0.01% 3247

Other funds holding LPCN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WE
Wealth Effects Boston, Massachusetts $370M AUM 97.79% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
KAS
Kestra Advisory Services Austin, Texas $31B AUM 28.39% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bank of New York Mellon's LPCN Position: Q2 2023 in Review

Bank of New York Mellon sold out of Lipocine (LPCN) in Q2 2023, closing a stake of 3,115 shares — an estimated $16.8K sold.

Bank of New York Mellon first reported a position in LPCN in Q3 2015 and held it in 28 quarters. The position peaked at $951K in Q4 2015. 24 funds tracked by Wall St. Rank hold LPCN as of Q2 2023.

  • Bank of New York Mellon reported no remaining Lipocine position as of Q2 2023 after selling out during the quarter.
  • Bank of New York Mellon sold 3,115 Lipocine shares in Q2 2023, an estimated $16.8K.
  • Bank of New York Mellon first reported a position in Lipocine in Q3 2015 and held it in 28 quarters.
  • Bank of New York Mellon's Lipocine position peaked at $951K in Q4 2015.
  • 24 funds tracked by Wall St. Rank held Lipocine as of Q2 2023.

Based on Bank of New York Mellon's 13F filing for Q2 2023, filed 3 Aug 2023.